Guggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potential

More in Finance

• The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%

  Soaring debt financing expenses and rising default insurance rates are squeezing artificial intelligence infrastructure developers across the technology sector. Investor scrutiny is rapidly intensifying as hyperscalers outpace their operating cash with aggressive capital expenditures, resulting in negative collective free cash flow. This growing financial friction threatens to disrupt aggressive buildout targets just as regulatory headwinds create project uncertainty.

  3 min read
• Raymond James upgrades Solaris to Strong Buy, sees tactical entry after selloff

  Analysts are taking an aggressive stance on the company following a period of sustained market pressure. The revised positioning suggests that recent price declines have created an attractive risk-reward profile for institutional and retail investors. This decisive rating change signals strong conviction in the asset's recovery potential going forward.

  1 min read
• Sweden stocks lower at close of trade; OMX Stockholm 30 down 1.01%

  The Nordic market faced downward momentum as broad selling pushed major equities into the red by the closing bell. This contraction reflects ongoing caution among regional market participants navigating prevailing economic headwinds. Investors are monitoring these losses to gauge broader sentiment across Scandinavian equity benchmarks.

  1 min read